Physician profile
Brian Patrick Wall
NPI 1821293689
$9,631.51
in general payments reported to CMS, 2019-2025
39 companies · $2,236 in 2025
The $2,236 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,095 · 2020: $327 · 2021: $601 · 2022: $813 · 2023: $2,075 · 2024: $2,485 · 2025: $2,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,795.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,830.27 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $866.99 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Medtronic, INC. | $737.29 | 2021-2025 | Symplicity G3, Onyx Frontier |
| Pfizer INC. | $669.52 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $519.52 | 2019-2024 | Xarelto |
| Amgen INC. | $466.03 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $452.01 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $396.00 | 2019-2024 | Watchman Flx, Watchman Access System, Bodyguardian |
| Merck Sharp & Dohme LLC | $380.64 | 2022-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $349.43 | 2020-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $326.89 | 2022-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.92 | 2022-2025 | Jardiance |
| Abbott Laboratories | $285.10 | 2020-2025 | Pressurewire, Diamondback Coronary, Xience Skypoint |
| Novo Nordisk INC | $257.32 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Chiesi USA, INC. | $239.62 | 2019-2025 | Kengreal, Cleviprex |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $201.73 | 2019 | |
| Alnylam Pharmaceuticals INC. | $178.68 | 2023-2025 | Onpattro, Amvuttra |
| Inari Medical, INC. | $175.64 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Sanofi-Aventis U.S. LLC | $174.16 | 2019-2023 | |
| Bridgebio Pharma, INC. | $103.85 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $92.16 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $68.62 | 2025 | |
| Impulse Dynamics (USA) INC. | $62.86 | 2025 | Optimizer |
| Cvrx, INC. | $50.88 | 2024-2025 | Barostim Neo System |
| Scpharmaceuticals INC. | $46.42 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $45.68 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $41.04 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $39.07 | 2024 | Arcalyst |
| Shockwave Medical, INC | $36.03 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cardiovascular Systems INC. | $33.30 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $30.35 | 2025 | Uptravi, Opsynvi |
| Abiomed | $28.48 | 2025 | |
| Gilead Sciences, INC. | $28.10 | 2019 | |
| Astellas Pharma US INC | $26.50 | 2019-2020 | |
| Corcept Therapeutics | $23.89 | 2025 | Korlym |
| Cordis US Corp. | $17.00 | 2025 | Mynx Control Venous |
| Daiichi Sankyo INC. | $14.59 | 2025 | Injectafer |
| Arbor Pharmaceuticals, INC. | $14.06 | 2019 | |
| Amarin Pharma, INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.